glp-1 agonists oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies FORMULATION DEVELOPMENT - Innovative Drug

These findings indicate that GIC-1001 is well-tolerated, with a safety profile comparable to placebo, and that its safety is consistent under both fed and fasted conditions

It is a GRAS-certified substance, meaning it has been determined by the FDA to be Generally Recognized as Safe

Importantly, there were no cardiovascular adverse events, no clinically significant changes in blood pressure or heart rate, no alterations in thyroid function, no immunogenicity with no anti-AOD-9604 antibodies detected, and no signs of tolerance or receptor desensitization

The capacity value comes in handy to measure how long the battery can supply the required power to the circuit when a given amount of current is drawn from the circuit